Literature DB >> 7511411

Nuclear DNA helicase II unwinds both DNA and RNA.

S Zhang1, F Grosse.   

Abstract

Nuclear DNA helicase II (NDH II) has been purified to near-homogeneity by exploiting its high affinity to poly[(rI).(rC)]-agarose. The purified enzyme was obtained as two catalytically active forms of 130- and 100-kDa molecular mass, respectively. After treatment with cyanogen bromide, the separated polypeptides displayed very similar digestion patterns. Thus, the 100-kDa form most likely is a proteolytic product of the 130-kDa polypeptide. For DNA unwinding, NDH II could use any of the four rNTPs or dNTPs with Km values between 20 and 100 microM. DNA unwinding was stimulated up to 20-fold by substrates that contained single-stranded 3'-tails. NDH II-catalyzed DNA unwinding was strongly inhibited by RNA, but was little affected by DNA. The strongest RNA inhibitor, poly[(rI).(rC)], was also the strongest effector of the NTPase activity of NDH II. The binding constant for poly[(rI).(rC)] binding was about 2 x 10(7) M-1; the minimal binding site size was determined as 16 nucleotides. In agreement with its high affinity to RNA, NDH II unwound double-stranded RNA. RNA unwinding required the presence of a nucleoside triphosphate and a divalent cation (Mg2+). Thus, like the prototypic replicative helicase large T antigen of simian virus 40, NDH II may function in both DNA and RNA unwinding.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511411     DOI: 10.1021/bi00179a016

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  41 in total

1.  The human coronavirus 229E superfamily 1 helicase has RNA and DNA duplex-unwinding activities with 5'-to-3' polarity.

Authors:  A Seybert; A Hegyi; S G Siddell; J Ziebuhr
Journal:  RNA       Date:  2000-07       Impact factor: 4.942

2.  Biochemical characterization of the equine arteritis virus helicase suggests a close functional relationship between arterivirus and coronavirus helicases.

Authors:  A Seybert; L C van Dinten; E J Snijder; J Ziebuhr
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

3.  Mtt1 is a Upf1-like helicase that interacts with the translation termination factors and whose overexpression can modulate termination efficiency.

Authors:  K Czaplinski; N Majlesi; T Banerjee; S W Peltz
Journal:  RNA       Date:  2000-05       Impact factor: 4.942

4.  Kaposi's sarcoma-associated herpesvirus viral protein kinase interacts with RNA helicase a and regulates host gene expression.

Authors:  Jae Eun Jong; Junsoo Park; Sunmi Kim; Taegun Seo
Journal:  J Microbiol       Date:  2010-05-01       Impact factor: 3.422

Review 5.  RNA helicases: emerging roles in viral replication and the host innate response.

Authors:  Arnaz Ranji; Kathleen Boris-Lawrie
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

6.  The RNA helicase DHX9 establishes nucleolar heterochromatin, and this activity is required for embryonic stem cell differentiation.

Authors:  Sergio Leone; Dominik Bär; Coenraad Frederik Slabber; Damian Dalcher; Raffaella Santoro
Journal:  EMBO Rep       Date:  2017-06-06       Impact factor: 8.807

7.  Human Nup98 regulates the localization and activity of DExH/D-box helicase DHX9.

Authors:  Juliana S Capitanio; Ben Montpetit; Richard W Wozniak
Journal:  Elife       Date:  2017-02-21       Impact factor: 8.140

8.  Members of the NF90/NFAR protein group are involved in the life cycle of a positive-strand RNA virus.

Authors:  Olaf Isken; Claus W Grassmann; Robert T Sarisky; Michael Kann; Suisheng Zhang; Frank Grosse; Peter N Kao; Sven-Erik Behrens
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

9.  Vaccinia virus RNA helicase: nucleic acid specificity in duplex unwinding.

Authors:  C H Gross; S Shuman
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  WRN helicase unwinds Okazaki fragment-like hybrids in a reaction stimulated by the human DHX9 helicase.

Authors:  Prasun Chakraborty; Frank Grosse
Journal:  Nucleic Acids Res       Date:  2010-04-12       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.